What SPF actually measures — and what it doesn't
SPF measures protection against ultraviolet B radiation only. UVA protection is indicated separately — in Europe via the UVA circle logo, in Korea via PA ratings (+, ++, +++, ++++). Broad-spectrum sunscreens with both UVB and UVA coverage are now standard.
What broad-spectrum does not cover is visible light — the 400–700 nm band of the electromagnetic spectrum that your eyes perceive as light. Visible light constitutes nearly half of all solar radiation reaching the skin. High-energy visible light, or HEVL — specifically blue light in the 400–490 nm range — has been shown to induce oxidative stress, trigger melanogenesis through opsin 3-mediated pathways, and degrade the dermal extracellular matrix. (Naidoo et al., Dermatology and Therapy, 2026)
The opsin 3 pathway is the key mechanism. It is completely separate from the UV-driven melanogenic cascade. This means that a patient wearing SPF 50+++ PA++++ — perfect UV protection — and sitting near a window on a cloudy day is still receiving a melanogenic stimulus that their sunscreen does nothing to block.
For patients with melasma, postinflammatory hyperpigmentation, or any UV-sensitive pigmentary condition, this is not a minor gap. It is a structural failure in the treatment approach.
The ingredient that closes the gap — and why it has to be visible
To protect against visible light, a sunscreen must be visible on the skin. This is the counterintuitive part.
The nanoparticle formulations of zinc oxide and titanium dioxide used in modern mineral sunscreens are specifically engineered to be invisible — to avoid the white cast that made earlier mineral sunscreens cosmetically unacceptable. The price of that cosmetic refinement is that nanoparticle zinc oxide and titanium dioxide do not protect against visible light. They scatter UV; they do not absorb the longer wavelengths that constitute visible light.
Iron oxides are different. Iron oxides absorb and scatter visible light. But they are pigments — they produce colour. A sunscreen containing iron oxides will always have a tint. That tint is not a cosmetic compromise. It is the mechanism. Tinted sunscreens containing iron oxides and pigmentary titanium dioxide reduce HEVL transmission by 80–97%, depending on formulation and iron oxide concentration. Darker formulations with higher iron oxide concentrations achieve the upper end of that range. (Naidoo et al., 2026)
A 2025 prospective randomised investigator-blinded study by Polena et al. directly compared tinted, visible-light-protective sunscreen against untinted SPF 50+ sunscreen in melasma patients over a summer period. Patients using the tinted formulation showed significantly better relapse prevention. Same UV protection factor. Different outcome. The only variable was visible light coverage.
What this means for patients managing pigmentation
If you are treating melasma, postinflammatory hyperpigmentation, or any condition where pigment control matters, and your photoprotection protocol uses an untinted sunscreen — even SPF 50, even PA++++ — you are leaving a biologically active pigmentary stimulus unaddressed every time your patient steps into daylight.
The clinical recommendation that follows from the evidence is straightforward: tinted sunscreen containing iron oxides should be standard in any photoprotection protocol for pigmentation-prone patients. Not as an add-on. As the baseline.
The objection I hear is cosmetic. Patients resist tinted sunscreen because they assume it will look like makeup, mismatch their skin tone, or feel heavy. The formulations available in 2026 — particularly Korean and European tinted mineral sunscreens — have addressed most of these concerns. Shade ranges have expanded. Textures have improved. The clinical argument for iron oxide protection is now stronger than the cosmetic argument against it.
The second objection is conceptual. Patients who have been diligently applying SPF 50 for years and still see pigmentation relapse often blame the treatment they were given, or assume their condition is simply uncontrollable. In most cases, what they were given was incomplete — not wrong, but incomplete. Half of the solar stimulus was never being blocked.
Visible light is not a new discovery. The evidence has been available for years. The sunscreen label just hasn't caught up — and neither has the conversation most patients are having with their clinicians.
Naidoo K, et al. Visible Light Protection Strategies for Diverse Populations. Dermatology and Therapy. 2026;16(2):833–854. doi:10.1007/s13555-025-01642-5
Polena H, et al. Comparison of Visible Light-Protective Tinted Sunscreen to Untinted Sunscreen to Protect Melasma Patients During Summer. J Cosmet Dermatol. 2025. PMC12475913
Clinical assessments available in Seoul — itsdrbock.com
